BIK is proposed to function as a tumour suppressor (see review Chinnadurai et al. 8 ). Deletions in regions of chromosome 22q, encompassing the BIK gene, have been reported in human colorectal as well as head and neck cancers and gliomas. Loss of heterozygosity at the BIK locus has been observed in renal cell carcinomas. Mutations within the BIK gene were found in human B-cell lymphomas and microarray analyses have revealed epigenetic silencing of BIK in multiple myeloma-derived cell lines.
To assess the tumour suppressor potential of Bik, we have examined the impact of Bik deficiency on lymphomagenesis in Em-Myc transgenic mice, which develop pre-B or B-cell lymphoma resulting from c-Myc overexpression followed by acquisition of additional oncogenic mutations. 9, 10 We found that loss of Bik, even in combination with loss of Noxa (which has a binding specificity complementary to Bik), did not accelerate Em-Myc-induced lymphomagenesis.
BIK-induced apoptosis has mainly been demonstrated in epithelial cancer-derived cell lines using in vitro overexpression systems. 5, 6, [11] [12] [13] [14] [15] [16] The role of endogenous Bik in chemotherapeutic drug-induced killing of cancer cells has not been examined in detail. Curiously, reports have described both p53-dependent 17, 18 and p53-independent 19, 20 transcriptional induction of Bik in response to anti-cancer therapeutics in human tumour-derived cell lines but the relevance of these findings is unclear. We have previously shown that Bik loss does not alter sensitivity of Em-Myc lymphoma cells with functional p53 to apoptosis induced by etoposide in vitro. 21 We show here that neither loss of Bik alone, nor the combined deficiency of Bik and Noxa, affect sensitivity of Em-Myc lymphomas to the DNA-damaging chemotherapeutic drug, cyclophosphamide (CTX) in vivo and demonstrate that loss of Bik and Noxa can be adequately compensated for by other BH3-only proteins in the response of lymphoma cells to DNAdamaging chemotherapy.
Results
Bik is expressed in El-Myc lymphoma cells. c-Myc overexpression upregulates the expression of the BH3-only genes Noxa, Puma and Bim 22 and loss of these proteins was shown to accelerate lymphomagenesis in Em-Myc transgenic mice. [22] [23] [24] [25] Similarly, pre-leukaemic B220 þ sIgM À pre-B and B220 þ sIg þ B-lymphoid cells from pre-malignant Em-Myc mice (4-6 weeks of age) displayed higher levels of Bik mRNA induction (B5-fold and B17-fold increase, respectively) compared with their counterparts from control (nontransgenic, wt) littermates ( Figure 1a) . Bik is expressed in a diverse range of haematopoietic cell types, 7 however, little has been reported about its levels in neoplastic haematopoietic cells. Higher levels of Bik mRNA were observed in Em-Myc pre-B lymphoma (B2-fold increase) and Em-Myc B-lymphoma cells (B7-fold increase) isolated from sick (tumourbearing) Em-Myc transgenic mice compared with normal pre-B and B-lymphoid cells from healthy C57BL/6 mice ( Figure 1b ).
Neither loss of Bik nor combined loss of Bik and Noxa accelerate El-Myc lymphoma development. Bik is not essential for normal mouse development and unstressed Bik À / À mice display no haematopoietic abnormalities despite its widespread expression in the haematopoietic compartment. 7 We examined the effect of BIK deficiency on Em-Myc-induced lymphomagenesis. Em-Myc mice (n ¼ 68) displayed a median survival of 106 days and Em-Myc/Bik Differences in the levels of mRNA for pro-apoptotic BH3-only genes between FACS-purified pre-B (B220 þ sIgM À ) and B (B220 þ sIgM þ ) cell subsets obtained from healthy 4-6-week-old Em-Myc mice (a) or from sick lymphoma-bearing Em-Myc mice (b), compared with the corresponding non-transformed pre-B and B-lymphoid cells from age-matched control C57BL/6 mice. Relative RNA expression levels were calculated by normalising to the b-actin signal in each sample, then dividing the values from the Em-Myc transgenic B-lymphoid or -lymphoma cells by the value from the control (nontransgenic) cells (represented by the dotted horizontal line at 1). Data represent mean expression ± S.E.M. of cells (lymphoma or control non-transformed) from three individual mice of each genotype analysed in three separate experiments. In pre-malignant Em-Myc B220 þ sIgM þ B cells, the fold induction of Bik mRNA compared with that observed in control nontransgenic B220 þ sIgM þ B cells, was significantly higher (*Po0.05) than the fold induction of Bad, Bid, Bim and Noxa Em-Myc mice 9, 10 with conspicuous enlargement of lymph nodes, spleen and thymus.
Given the complementary binding patterns of the BH3-only proteins NOXA (MCL-1, A1) and BIK (BCL-2, BCL-X L , BCL-W) to pro-survival BCL-2 family members 2, 26 and the report that, when enforcibly expressed, these two BH3-only proteins can cooperate to induce BAX activation, resulting in mitochondrial release of cytochrome c, 15 we generated Em-Myc mice doubly-deficient for Noxa and Bik. As reported previously, 22 loss of Noxa did not significantly affect Em-Mycinduced lymphomagenesis with Em-Myc/Noxa À / À mice displaying a median survival of 133 days (n ¼ 64) compared with a median survival of 106 days in control Em-Myc mice (n ¼ 68) (Figure 2a ). Even the combined loss of both Bik and Noxa did not accelerate Em-Myc-induced lymphomagenesis (median survival 100 days; n ¼ 27; Figure 2a) .
qRT-PCR analysis of Em-Myc/Bik À / À and Em-Myc/Bik À / À Noxa À / À lymphomas showed no significant differences in expression levels of the pro-apoptotic BH3-only genes Bad, Bim, Bmf, Puma, Noxa, or of the pro-survival Bcl-2 family genes, Bcl-2, Bcl-x, Mcl-1 when compared with control EmMyc lymphoma cells (Figure 3a ). These results demonstrate that loss of Bik, or even combined loss of Bik and Noxa, two BH3-only proteins with complementary binding specificity for Bcl-2-like pro-survival proteins, does not cause compensatory upregulation of the other remaining BH3-only genes, or changes in expression of pro-survival Bcl-2 genes at the transcript level.
Loss of Bik alone, or in combination with Noxa loss has no effect on disease severity or lymphoma subtype in Em-Myc transgenic mice. Immunophenotyping of primary lymphomas revealed that the majority were either B220 Differences in tumour onset depending on tumour immunophenotype in Em-Myc mice lacking single BH3-only proteins have been documented. Loss of BIM, PUMA, BMF or BAD accelerated Em-Myc B-cell lymphoma development while the onset of pre-B lymphomas was not altered. 22, 23, 25 These data indicate that BH3-only proteins exert differentiation stagespecific suppressive effects on lymphomagenesis and highlight the necessity of analysing the impact of BH3-only protein deficiencies on tumourigenesis, with respect to immunophenotype. Tumour onset in Em-Myc, Em-Myc/Bik À / À and EmMyc/Bik À / À Noxa À / À mice was therefore stratified according to pre-B or B lymphoma subtype. No significant differences in survival were observed between Em-Myc/Bik À / À mice bearing pre-B (median survival 145 days, n ¼ 9) or mature B cell (median survival 128 days, n ¼ 11) lymphomas versus control Em-Myc mice bearing pre-B (median survival 202 days, n ¼ 10) or B cell (median survival 125 days, n ¼ 14) lymphomas (Figure 2b) . Similarly, the survival of Em-Myc/ 
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The incidence of p53 pathway mutations in El-Myc lymphomas is not altered as a result of Bik deficiency or combined deficiency of Noxa and Bik. There is significant pressure for the p19 ARF -p53 pathway to be compromised during Em-Myc-induced lymphoma development. 27 Loss of certain BH3-only proteins, such as BIM, 23 (Figure 5a ). As p53 normally regulates p19 ARF protein expression by a negative feedback loop in healthy cells 27 (Figure 5d ), the levels of p19 ARF as well as p53 protein were examined by western blotting in a panel of randomly selected Em-Myc/Bik À / À , Em-Myc/Bik À / À Noxa À / À and control Em-Myc lymphomas. In these assays high levels of p19 ARF indicate loss of p53 function because of impaired negative regulation; 29 and high levels of p53 indicate mutant, stabilised p53. High p19 ARF and/ or p53 protein levels were detected in 3/20 (15%) Em-Myc/ Bik À / À and in 3/10 (30%) Em-Myc/Noxa À / À (Figures 5b and  c) lymphomas. This prevalence was comparable to that seen in control Em-Myc lymphomas (2/15 (13.3%) as well as to the previously published incidence of 3/10 (30%) in Em-Myc/ Noxa À / À lymphomas. p53-independent Bik induction occurs following DNAdamaging drug treatment in El-Myc lymphomas. Stable cell lines were generated from lymphomas from sick control Em-Myc or p53-deficient Em-Myc mice. Upon in vitro treatment of control Em-Myc and Em-Myc/p53 À / À lymphoma cell lines with 0.2 mg/ml etoposide for 3, 6 or 8 h, only negligible induction of Bad, Bid and Bmf was observed (Figure 6a ). Bim mRNA, concordant with our previous findings, 21 was markedly induced in Em-Myc lymphoma cell lines and was significantly less pronounced in Em-Myc lymphoma cell lines lacking p53. Similarly, Bik mRNA was upregulated, albeit at slightly lower magnitude than Bim (B4-fold vs B8-fold at 6 h, respectively; Figure 6a ). However, in contrast to Bim, Bik mRNA induction (B3-fold at 6 h and B7-fold at 8 h) was also upregulated at similar levels in Em-Myc/p53
À / À lymphoma cell lines (Figure 6a ), demonstrating that this transcriptional induction is p53-independent.
Loss of Bik alone, or in combination with Noxa loss does not render El-Myc lymphoma cells resistant to DNAdamaging drug-induced killing. Although Bik mRNA is induced in Em-Myc lymphoma cells following etoposide treatment, we have shown previously that Em-Myc/Bik À / À lymphoma cell lines display sensitivity to etoposide, comparable to that of conventional Em-Myc lymphoma cell lines. 21 The potential for important co-operation between BIK and other BH3-only proteins could not be excluded. We therefore investigated the possible co-operation between BIK and NOXA in DNA damage-induced killing of lymphoma cells. Analysis of stable cell lines from four independent lymphomas arising in Em-Myc/Bik À / À Noxa À / À mice revealed that concomitant loss of BIK and NOXA did not afford significant protection from etoposide-induced killing (Figure 6b) .
The role of Bik in DNA-damaging drug-induced apoptosis was further assessed in vivo by transplanting primary lymphomas into immuno-competent C57BL/6-recipient mice. Once tumours became palpable, the mice were treated with SV40  73  318  208  432  97  128  25   MEF  MEF   SV40  208  410  35  323  32  515  464  SV40  208  672  467  548  718  470  713 Table 2 ). The in vivo survival data were analysed using Cox proportional hazards models, taking into account the correlation between recipient mice. No significant difference post-CTX treatment was observed between the survival of mice bearing control Em-Myc (blue curves) and Em-Myc/Bik À / À (orange curves) lymphomas (P ¼ 0.869 for 200 mg/kg body weight CTX, P ¼ 0.336 for 300 mg/kg body weight CTX) or between the survival of mice bearing control Em-Myc (blue curves) and Em-Myc/Bik À / À Noxa À / À (green curves) lymphomas (P ¼ 0.637 for 200 mg/kg body weight CTX; P ¼ 0.212 for 300 mg/kg body weight CTX) ( Figure 6c ). As expected, Em-Myc lymphomas with a mutated p53-p19 ARF pathway (red curves) displayed profound resistance to CTX and mice bearing such tumours died rapidly following treatment. Consistent with the in vitro data, neither lymphomas lacking Bik alone, nor those lacking both Bik and Noxa, displayed an increase in resistance to CTX treatment in vivo compared with lymphomas with endogenous levels of Bik and Noxa.
Discussion
Bik-deficient mice develop normally with a normal lifespan. 7 Non-transformed haematopoietic cells and fibroblasts from these mice respond normally to various apoptotic stimuli, including DNA damage. 7 Although these results would suggest functional redundancy between BIK and other pro- apoptotic BH3-only proteins, BIK has been proposed to function as a tumour suppressor in several human cancers, including some lymphoid malignancies. 8 Apoptosis triggered by c-Myc overexpression is regulated by the BCL-2 protein family 30, 31 and is thought to impose a major barrier to MYC-induced lymphoma development. Accordingly, overexpression of pro-survival BCL-2 32 or loss of BH3-only proteins that have potent killing capacity, such as BIM 23, 28 and PUMA 22, 24 can significantly accelerate MYCinduced lymphomagenesis in mice. A recent study showed that loss of the more 'selective' binders, and therefore less potent BH3-only proteins, BMF and BAD, can also accelerate Em-Myc-driven lymphomagenesis. 25 These data are somewhat surprising given that theoretically, the promiscuous BIM or PUMA could adequately compensate for loss of either BMF or BAD. These findings indicate that the role of selective BH3-only proteins in tumour suppression may not simply be redundant to the functions of 'potent' BH3-only proteins and the control of survival of cells undergoing neoplastic transformation is not solely dictated by the sequestration of prosurvival BCL-2 family proteins. 33 We therefore reasoned that BIK might also constrain tumour development in the context of c-MYC overexpression.
Bik mRNA expression levels were modestly elevated in preleukaemic, B-lymphoid cells from pre-malignant Em-Myc mice compared with those from control (WT) mice. Moreover, lymphoma cells from sick Em-Myc mice also expressed readily detectable levels of Bik mRNA. These observations support the notion that BIK may have a role in suppression of Em-Mycinduced lymphomagenesis. Induction of apoptosis by c-MYC overexpression is attributable in part to activation of the p19 ARF -p53 pathway, in which p19 ARF upregulation prevents the degradation of p53 by sequestration of the ubiquitin ligase MDM2. 27, 34 The link between Bik levels and p53, however, is controversial. Although putative p53 binding sites have been identified in the promoter of the Bik gene 35 and ectopic overexpression of p53 has been shown to robustly induce Bik expression, 17 a p53 response could not be detected in promoter/reporter assays. 17, 18 c-MYC overexpression can, however, also induce apoptosis independent of p53 18, 27 and thus, the elevation of Bik we observed may be critical for apoptosis induction independent of p53.
Despite evidence of loss of BIK expression in human tumours, 8 in the Em-Myc transgenic mouse model, loss of BIK was insufficient to accelerate lymphoma onset or increase disease severity. Time to tumour morbidity (when animals have to be killed) has been demonstrated to differ according to immunophenotype (sIgM À pre-B or sIgM þ B cell) of lymphomas in Em-Myc mice lacking certain BH3-only genes. For example, loss of BIM, PUMA, BMF or BAD accelerated development of Em-Myc B-cell lymphoma while the onset of pre-B lymphoma was unaltered. 22, 23, 25 Moreover, loss of NOXA delayed the onset of Em-Myc pre-B lymphomas but not Em-Myc B-cell lymphomas. 22 In comparison, BIK deficiency had no impact on pre-B or B-cell Em-Myc lymphoma development, implying that BIK may have overlapping functions with other BH3-only proteins. BIK may still be a barrier to tumour development in other cell types, both haematological and nonhaematological, or in tumourigenesis driven by distinct oncogenic lesions (unrelated to c-MYC overexpression). Alternatively, the lack of effect on tumourigenesis may reflect BIK's ability to sequester only select prosurvival BCL-2 family proteins. 2, 26 Therefore, the disturbance of the overall balance between pro-apoptotic and antiapoptotic BCL-2 family members caused by BIK loss would be relatively minor, as loss of BIK can theoretically be compensated for by several other (selective binding) proapoptotic BH3-only proteins (such as BMF and BAD) and loss of BIK would not be expected to impact on inhibition of either MCL-1 or A1.
The lack of protection of Em-Myc lymphomas from DNAdamaging drug-induced killing conferred by loss of BIK stands in contrast to studies in which ectopic overexpression of BIK was used to potently induce apoptosis in tumour-derived cell lines. 5, 6, 11, 12, 14 Overexpression may allow BIK to artificially interact with and inhibit a wider array of pro-survival BCL-2 proteins 2,5,6 than does endogenous BIK, expressed under physiological conditions. Nonetheless, it is curious that we and others 19, 20 have observed a modest induction of Bik following DNA damage, independent of p53. As its loss had little impact on the apoptotic response of lymphoma cells, it is unclear whether Bik induction contributes to apoptosis induction in this setting. The p53-independent upregulation of Bik may function to amplify the response to DNA-damaging drugs observed in Em-Myc lymphomas that is elicited by the major p53-dependent apoptosis inducers, PUMA and NOXA.
Enforced co-expression of BIK and NOXA can cooperate potently in killing mouse embryonic fibroblasts (MEFs) 2 and in H1299 cells, to synergise in inducing BAX activation and cytochrome c release from mitochondria. 15 This cooperative action is presumably due to the complementary nature of their binding abilities to pro-survival BCL-2 family members.
2 BIK and NOXA together can theoretically complement one another to allow sufficient neutralisation of all pro-survival BCL-2-like proteins in a cell to promote more potent apoptosis induction than would be possible with sole expression of either protein. We have found, however, that a combined deficiency in BIK and NOXA is not sufficient for acceleration of Em-Mycinduced lymphoma development or to increase resistance of Em-Myc lymphoma cells to DNA-damaging drug-induced apoptosis indicating that other BH3-only proteins, such as potent family members, PUMA and BIM, can still adequately compensate for their loss. Loss of both BIK and NOXA did not significantly alter the transcription of other pro-apoptotic BH3-only genes, such as Bad, Bim, Puma and Bmf or pro-survival genes, such as Bcl-2, Bcl-xl or Mcl-1, although alterations in the post-transcriptional regulation of these BCL-2 family members cannot be excluded.
Functionally relevant inhibition of the apoptotic signalling pathway downstream of p53, such as that afforded by loss of PUMA or by the combined loss of PUMA and NOXA, have been shown to diminish the pressure for p19 ARF -p53 pathway mutations in c-MYC overexpression-driven lymphomas, 22, 24 as has loss of BIM 23 or BMF (but not loss of BAD). 25 Deficiency in BIK alone was not able to diminish the selection for loss of p53 function, indicating that loss of BIK cannot compensate for loss of p53. This indicates that the levels of the more potent (promiscuous binding) BH3-only proteins PUMA and BIM are sufficient in Em-Myc transgenic pre-B/ B-lymphoid cells to delay neoplastic progression.
Collectively, studies of BH3-only gene deletion in the Em-Myc lymphoma model highlight the intricacies of apoptotic regulation in response to oncogene activation and DNA damage. The life or death fate of cells undergoing neoplastic progression or of transformed cancer cells following treatment with anti-cancer drugs must not simply be governed by the overall balance of pro-and anti-apoptotic BCL-2 family members, but instead requires the activation of distinct BH3-only proteins for apoptosis induction in a cell-type-and stimulus-specific manner. Thus Bik, even in combination with Noxa, is not a potent suppressor of c-Myc-driven tumourigenesis or critical for chemotherapeutic drug-induced killing of Myc-driven tumours. Bik À / À 7 and p53 À / À 37 mice (all on a C57BL/6 background) have been described. The former two strains were generated on an inbred C57BL/6 background using C57BL/ 6-derived ES cells; the p53 À / À mice were generated on a mixed C57BL/6 Â 129SV background, using 129SV-derived ES cells, but were backcrossed with C57BL/6 mice for 410 generations. Em-Myc transgenic males were crossed with p53 À / À or p53 El-Myc lymphomas and lymphoma cell lines. Em-Myc lymphomas were defined by flow cytometry as either pre-B (B220 þ sIg À ) or B-cell lymphomas (B220 þ sIgM þ ). Lymphoma cells were used for either transplantation into C57BL/6-recipient mice for in vivo drug sensitivity analysis or for in vitro culture to obtain stable lymphoma cell lines. Lymphoma cell lines were generated by preparing single-cell suspensions from spleen, which were cultured at 37 1C in a humidified 10% CO 2 incubator in high-glucose Dulbecco's modified Eagle's medium supplemented with 10% foetal calf serum (JRH Biosciences, Brooklyn, VIC, Australia), 50 mM 2-mercaptoethanol (Sigma) and 100 mM asparagine (Sigma) referred to as FMA.
Western blotting. Protein samples were size-fractionated by SDS-PAGE and then blotted onto nitrocellulose (Invitrogen, Grand Island, NY, USA) membranes. Membranes were blocked with 5% non-fat dry milk (Devondale, Melbourne, VIC, Australia) in PBS with 0.1% Tween 20 (Sigma) and then probed with antibodies against p53 (CM5, Novacastra, North Ryde, NSW, Australia), p19 ARF (AbCam, Waterloo, NSW, Australia) and b-ACTIN (clone AC-74, Sigma; used as a loading control). Detection was performed with HRP-conjugated secondary antibodies and enhanced chemiluminescence (Amersham Biosciences, Castle Hill, NSW, Australia).
Quantitative reverse transcription (qRT)-PCR. Cells were given a DNA damage insult (etoposide) in the presence of QVD-OPH to prevent terminal cellular destruction, and RNA was isolated at specific time points following treatment. Total RNA was extracted from 0.5-1 Â 10 6 cells using the TRIzol Reagent (Invitrogen) according to the manufacturer's instructions. 0.5-1 mg of total RNA was converted to cDNA using the High Capacity RNA to cDNA kit (Applied Biosystems, Mulgrave, VIC, Australia). For quantitative analysis, the resulting cDNA was subjected to PCR in 10 ml reaction volumes using Taqman Universal PCR Master Mix (Applied Biosystems) with Taqman Gene Expression Assays (Applied Biosystems) and assessed on an ABI-PRISM 7900 thermal cycler (Applied Biosystems). b-Actin served as an endogenous normalisation control. Data analyses were performed by the comparative threshold cycle method.
Cell death assays. Em-Myc lymphoma cells were cultured in FMA at a concentration of 25 000-50 000 cells per well in 96-well flat bottom microtiter plates (Falcon, North Ryde, NSW, Australia). Cells were exposed to etoposide/VP16 (Pfizer, West Ryde, NSW, Australia) (1, 0.2 or 0.04 mg/ml) for 6 or 24 h. Cell death was assessed by flow cytometric analysis after staining with propidium iodide (PI; 2 mg/ml) and annexin V-FITC (0.3 mg/ml). The extent of apoptosis induced specifically by treatment with a DNA damage inducing chemotherapeutic drug (percent specific apoptosis) was calculated using the following equation: [% induced apoptosis -(% spontaneous apoptosis/100 -% spontaneous apoptosis)]. Each independent Em-Myc lymphoma-derived cell line was analysed in at least three independent experiments.
In vivo lymphoma cell survival analysis post treatment with DNA-damaging drugs. Six-to 8-week-old C57BL/6 female mice were injected (i.v.) on day 0 with 2 Â 10 6 Em-Myc lymphoma cells. Mice were treated with CTX (200-300 mg/kg) or vehicle alone when their spleens became palpable (usually 10-16 days post tumour injection). Mice were culled when deemed unwell (lethargy, tremor, hind-leg paralysis, 45% weight loss, palpable tumour) in accordance with ethical guidelines, or in the absence of symptoms of lymphoma at 180 days post treatment (when these experiments were terminated).
Analysis of cdkn2a locus. Multiplex PCR analysis of genomic DNA extracted from lymphoma cells for the cdkn2a (p16 Ink4a /p19 Arf ) locus was performed to reveal gross deletions, using exon-specific primers for a-actin, exons 2, 1a and 1b as previously described. 38, 39 Histology. Soft tissues (spleen, lymph nodes, liver, kidney, heart, lung, thymus) and sternum were fixed in 10% buffered formalin. Tissues were embedded in paraffin, sectioned and stained using haematoxylin and eosin.
Statistical analysis. Prism (GraphPad Prism, GraphPad Software Inc., La Jolla, CA, USA), Stata 9.2 (StataCorp., College Station, TX, USA) and R (www.r-project.org) software were used for statistical analysis. Two-group comparisons of leukaemic burden, lymphocyte counts and spleen weights used two-tailed t-tests assuming equal variances.
Survival data were plotted using Kaplan-Meier curves. Differences in survival time to tumour-related deaths of Em-Myc mice of various genotypes were tested using log-rank tests (each independent lymphoma analysed separately). P values o 0.05 were considered to indicate statistical significance.
The survival data on lymphoma-burdened mice following in vivo treatment with CTX involved two-levels of biological replication, with many independently derived lymphomas of different genotypes and varying numbers of recipient mice per treatment arm per independent lymphoma (Supplementary Table 2 ), meaning that the survival times of recipient mice burdened with the same lymphoma were statistically dependent. To produce the Kaplan-Meier plots in Figure 6c , the median survival time was calculated separately for censored and non-censored mice for each independent lymphoma. The resulting Kaplan-Meier curves correspond to independent lymphoma rather than to recipient mice, and hence are statistically independent. To test whether the survival times of the different genotypes were significantly different, Cox proportional hazards regression models (Cox, 1972) were fitted. The correlations between recipient mice were taken into account using a robust sandwich estimator, implemented as method stcox cluster in Stata 9.2, to estimate S.E. from the Cox model. AS (#461299), GKS (#575515)); the Leukaemia and Lymphoma Society (New York; SCOR grant #7015), the National Cancer Institute (NIH, US; CA 80188 and CA 43540) and the Victorian Cancer Council Fellowship CLS (CRF10_20) and scholarships from The Leukaemia Foundation Australia (PhD scholarship to LH), and the University of Melbourne (PhD scholarship to BP). This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS.
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